Table 4.
Odds ratio (OR) and 95% confidence interval (CI) of clinical status and FUT2 rs1047781 genotypic frequencies in 339 HCC patients.
| Variable | Genotypic frequencies | |||
|---|---|---|---|---|
| AA (N = 95) | AT + TT (N = 244) | OR (95% CI) | p-value | |
| HCC stage | ||||
| I or II | 70 (73.7%) | 152 (62.3%) | 1.00 | 0.048* |
| III or IV | 25 (26.3%) | 92 (37.7%) | 1.695 (1.003-2.865) | |
| Tumor size | ||||
| ≤T2 | 72 (75.8%) | 153 (62.7%) | 1.00 | 0.022* |
| >T2 | 23 (24.2%) | 91 (37.3%) | 1.862 (1.089-3.183) | |
| Lymph node metastasis | ||||
| No | 91 (95.8%) | 237 (97.1%) | 1.00 | 0.531 |
| Yes | 4 (4.2%) | 7 (2.9%) | 0.672 (0.192-2.350) | |
| Distant metastasis | ||||
| No | 89 (93.7%) | 232 (95.1%) | 1.00 | 0.606 |
| Yes | 6 (6.3%) | 12 (4.9%) | 0.767 (0.279-2.107) | |
| Vascular invasion | ||||
| No | 82 (86.3%) | 196 (80.3%) | 1.00 | 0.197 |
| Yes | 13 (13.7%) | 48 (19.7%) | 1.545 (0.795-3.003) | |
| Child-Pugh grade | ||||
| A | 75 (78.9%) | 183 (75.0%) | 1.00 | 0.444 |
| B or C | 20 (21.1%) | 61 (25.0%) | 1.250 (0.705-2.215) | |
| HBsAg | ||||
| Negative | 58 (61.1%) | 140 (57.4%) | 1.00 | 0.537 |
| Positive | 37 (38.9%) | 104 (42.6%) | 1.164 (0.718-1.890) | |
| Anti-HCV | ||||
| Negative | 41 (43.2%) | 136 (55.7%) | 1.00 | 0.037* |
| Positive | 54 (56.8%) | 108 (44.3%) | 0.603 (0.374-0.973) | |
| Liver cirrhosis | ||||
| Negative | 20 (21.1%) | 47 (19.3%) | 1.00 | 0.710 |
| Positive | 75 (78.9%) | 197 (80.7%) | 1.118 (0.621-2.010) | |
The ORs and their 95% CIs were estimated by logistic regression models. >T2: multiple tumors of >5 cm in diameter or tumor(s) involving a major branch of the portal vein or hepatic veins. *p < 0.05.